HB-500 is a next-generation therapeutic vaccine being developed in collaboration with Gilead Sciences, Inc. (Gilead) as a potential component of ...

Driven by rapid innovations and the integration of modern technologies, the biotech sector is experiencing robust growth.

Gilead Sciences, Inc. (NASDAQ:GILD), a leading biopharmaceutical company with a market capitalization of $119.32 billion, has been making significant strides in its core HIV franchise while expanding ...

Gilead Sciences Inc. closed 3.35% below its 52-week high of $98.90, which the company achieved on November 11th.

In the assessment of 12-month price targets, analysts unveil insights for Gilead Sciences, presenting an average target of ...